Stock Movers Gemini Space Station Rises, Oracle Slumps, Eli Lilly Rises on Experimental Shot Cutting Weight
Dec 11, 2025
Gemini Space Station's shares soar after securing a CFTC license for U.S. prediction markets, hinting at exciting growth ahead. In contrast, Oracle struggles as its cloud sales forecast disappoints, raising red flags about revenue conversion. Meanwhile, Eli Lilly's new obesity drug impresses, leading to nearly a 25% weight loss in patients, positioning it as a potential frontrunner in weight-loss treatments. Stay tuned for more insights in the market!
AI Snips
Chapters
Transcript
Episode notes
Gemini Gets CFTC License
- Gemini Space Station's CFTC license lets U.S. customers trade prediction markets on its platforms.
- Analysts expect the license to boost user base and transaction volume despite the stock still being down from its IPO.
Oracle's Cloud Growth Disappoints
- Oracle warned third-quarter cloud sales will grow below expectations, fueling investor concern.
- Analysts worry supply constraints and competition could prevent backlog conversion into profitable revenue.
Eli Lilly's Potent Weight-Loss Results
- Eli Lilly's experimental obesity shot produced over 23% body-weight loss at the highest dose in 68 weeks.
- Analysts call it potentially best-in-class and expect more news through 2026.